

WEST[Help](#) [Logout](#) [Interrupt](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#) [Preferences](#) [Cases](#)**Search Results -**

Term	Documents
IL-21	263
IL-21S	0
(1 AND IL-21).PGPB.	1
(L1 AND 'IL-21').PGPB.	1

Database:

- [US Patents Full-Text Database](#)
- [US Pre-Grant Publication Full-Text Database](#)
- [JPO Abstracts Database](#)
- [EPO Abstracts Database](#)
- [Derwent World Patents Index](#)
- [IBM Technical Disclosure Bulletins](#)

Search: [Refine Search](#)

 [Clear](#)**Search History****DATE:** **Tuesday, September 16, 2003** [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
---------------------------------	--------------	------------------	-------------------------------

DB=PGPB; PLUR=YES; OP=ADJ

<u>L2</u>	L1 and 'il-21'	1	<u>L2</u>
<u>L1</u>	dumoutier.in.	6	<u>L1</u>

END OF SEARCH HISTORY

WEST

End of Result Set

 [Generate Collection](#) [Print](#)

L2: Entry 1 of 1

File: PGPB

Jan 16, 2003

DOCUMENT-IDENTIFIER: US 20030012788 A1

TITLE: Method for influencing kinase pathways with IL-22

INVENTOR (3):Dumoutier, LaureSummary of Invention Paragraph (4):

[0003] Interleukin-22, or "IL-22" hereafter, is an IL-10 related cytokine, that had previously been referred to as "TIF" or "IL-TIF" for "interleukin-10 related, T cell inducible factor." See U.S. Pat. Nos. 6,359,117; 6,331,163 and 6,274,710, as well as Dumoutier, et al., J. Immunol 164:1814-1819 (2000), all of which are incorporated by reference in their entirety. The molecule belongs to a family of cytokines with limited homology to IL-10, including IL-10, IL-22, mda-7/IL-24, IL-19, IL-20 and AK155/IL-26. See Moore, et al., Annu. Rev. Immunol 19:683-765 (2001); Dumoutier, et al., Eur. Cytokine Netw 13(1):5-15 (2002). The cytokine shows 22% amino acid identity with IL-10. Functionally, IL-22 activities which have been identified include upregulation of acute-phase reactants in liver and hepatoma cells (Dumoutier, et al., *supra*), as well as induction of pancreatitis-associated protein (PAP 1), in pancreatic acinar cells (Aggarwal, et al., J. Interferon Cytokine Res. 21:1047-1053 (2001)), suggesting a role for the cytokine in inflammatory processes. In addition, IL-22 has been shown to induce STAT activation in several cell lines, including mesangial cells, lung and intestinal epithelial cells, melanomas, and hepatomas. See Dumoutier, et al., *supra*; Dumoutier, et al., Proc. Natl. Acad. Sci USA 97:10144-10149 (2000); also see patent application Ser. No. 09/626,617, filed Jul. 27, 2000, incorporated by reference which referred to "TIF" as IL-21; however, the molecule has been renamed as IL-22.

WEST

Search Results - Record(s) 1 through 1 of 1 returned.

1. Document ID: US 20030012788 A1

L2: Entry 1 of 1

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030012788
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030012788 A1

TITLE: Method for influencing kinase pathways with IL-22

PUBLICATION-DATE: January 16, 2003

INVENTOR- INFORMATION:

NAME
 Renauld, Jean-Christophe
 Lejeune, Diane
Dumoutier, Laure

CITY	STATE	COUNTRY	RULE-47
Brussels		BE	
Brussels		US	
		BE	

US-CL-CURRENT: 424/145.1; 435/6, 435/7.21



Term	Documents
IL-21	263
IL-21S	0
(1 AND IL-21).PGPB.	1
(L1 AND 'IL-21').PGPB.	1

Display Format:

Previous Page Next Page